• About Us
  • Privacy Policy
  • Terms of Services
  • Contact
Tech News, Magazine & Review 2025
  • Home
  • About
  • Newsroom
  • FAQs
  • Submit Press Release
No Result
View All Result
My Account
  • Home
  • About
  • Newsroom
  • FAQs
  • Submit Press Release
No Result
View All Result
FirstPublisher
No Result
View All Result
Home Go Media

2025 AHA CME Symposium – Exploring the Evidence GLP-1 RAs in Individuals with T2D and ASCVD

by News Desk
October 9, 2025
2025 AHA CME Symposium – Exploring the Evidence GLP-1 RAs in Individuals with T2D and ASCVD
Share on FacebookShare on Twitter

This CME Symposium takes place on Sunday, November 9, 2025, from 7:00 PM – 8:30 PM CT during the 2025 Scientific Sessions of the American Heart Association in New Orleans, Louisiana.

HAZLET, N.J. – In this symposium, an expert faculty will discuss the data with injectable GLP-1 RAs in ASCVD patients and the place of injectable GLP-1 RAs in reduction of cardiovascular risk. The design, efficacy and safety results from the SOUL trial will be presented, as well as the latest meta-analyses with GLP-1 RAs. Cases of patients with T2D and ASCVD will be presented, and attendees will be provided with best practices incorporating evidence-based clinical decision making and patient-centered care.

Click here for more information (https://symposiareg.com/22510/)

CHAIR

Darren McGuire, MD MHSC

Distinguished Chair in Cardiovascular Science
Distinguished Teaching Professor
University of Texas Southwestern Medical Center
Dallas, Texas

FACULTY

Lawrence Letter, MD, FRCPC

Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario, Canada

Neha Pagidipati, MD, MPH
Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina

Richard Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
AdventHealth Translational Research Institute
Medical Director, AdventHealth Diabetes Institute
Orlando, Florida

Educational Objectives
– Describe the key injectable GLP-1 RA clinical trials and meta analyses in patients with T2D and high ASCVD risk
– Explain the American Diabetes Association 2025 guideline recommendations for the use of GLP-1 RAs in patients with T2D and ASCVD or multiple risk factors for ASCVD
– Interpret the evidence from the SOUL trial and describe the potential role for oral GLP-1 RA therapy in patients with T2D and high risk

Target Audience
This program is intended for cardiovascular clinicians and other healthcare professionals who manage patients with T2D and ASCVD risk.

Educational Grant
Voxmedia International gratefully acknowledges the educational grant from Novo Nordisk Inc.

Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live activity for a maximum of 1.5 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

News Desk
News Desk

News Desk

Recommended.

Crypto News: Pepeto Announces Binance Level Exchange Update While Ethereum Price Prediction Maps Path to $7,500

155
Private Keys Are a Single Point of Failure Security Advisor Gideon Cohen Warns MPC Technology Is Now the Only Defense for Institutional Custody - FirstPublisher.org

Private Keys Are a Single Point of Failure: Security Advisor Gideon Cohen Warns MPC Technology Is Now the Only Defense for Institutional Custody

153

Trending.

Anchored in the Asia-Pacific region, practicing inclusive finance: Noemon Finance’s 2026 global strategic upgrade reshapes the new paradigm of mass asset allocation.

158
Pixel Web Solutions Redefines DEX Market with Scalable Uniswap Clone Development Services - FirstPublisher.org

Pixel Web Solutions Redefines DEX Market with Scalable Uniswap Clone Development Services

161

Public Relations Indonesia Is Rethinking the Invisible Work Behind Agency Growth

157

TKROBOTS Introduces AI Quant Trading Bot to Make Automated Crypto Trading Easier for Everyday Users

156

Chintai launches CLV, a global AI-powered quantitative computing power financial ecosystem platform, exploring new paths for the integrated development of AI and RWA.

156
  • About Us
  • Privacy Policy
  • Terms of Services
  • Contact
Telegram: @FirstPublisher

© 2025 Firstpublisher

No Result
View All Result
  • Home

© 2025 Firstpublisher